Want to see SE:ACE full AI Analyst Report?
ACE Stock Chart & Stats
kr3.17
-kr0.11(-3.47%)
At close: 4:00 PM EST
kr3.17
-kr0.11(-3.47%)
Day’s Range― - ―
52-Week Rangekr0.46 - kr3.55
Previous CloseN/A
Volume171.87K
Average Volume (3M)718.29K
Market Cap
kr105.76M
Enterprise Valuekr352.94
Total Cash (Recent Filing)kr38.05M
Total Debt (Recent Filing)kr490.00K
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding133,535,460
10 Day Avg. Volume431,983
30 Day Avg. Volume718,292
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)3.67
Price to Sales (P/S)0.00
P/FCF Ratio-5.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.27
Revenue Forecast (FY)kr6.10M
Bulls Say, Bears Say
Bulls Say
Very Low LeverageMinimal leverage reduces solvency and refinancing pressure while preserving financial flexibility for continued clinical development. A largely unlevered balance sheet can also make it easier to pursue partnerships or raise capital without adding substantial interest obligations before commercialization.
Improving Losses And Cash BurnThe improvement from earlier loss and burn peaks indicates some progress in controlling development spending, even though the company remains unprofitable. If sustained, better cost discipline could extend the funding runway and support execution while Orviglance advances toward potential approval.
Differentiated Orviglance OpportunityOrviglance targets a defined oncology imaging need with an administration route and use case differentiated from conventional gadolinium-based agents. Successful development and approval could give Ascelia a focused product platform addressing an identifiable clinical gap in liver imaging.
Bears Say
Pre-Revenue Business ModelThe absence of operating revenue means the company has not yet demonstrated product-market adoption, pricing power, or commercial execution. Near-term business value remains tied to regulatory and launch milestones, leaving limited diversification if the lead product is delayed or unsuccessful.
Persistent Negative Cash FlowContinued operating and free-cash-flow deficits require the company to fund research and clinical activity without internally generated cash. This dependence on external capital can constrain development plans, dilute existing holders, and increase financial risk until a marketed product produces recurring receipts.
Eroding Equity BaseSustained losses are reducing the capital base despite very low debt, weakening the balance-sheet cushion available to absorb setbacks. Continued erosion may limit strategic flexibility and make future financing increasingly important for maintaining development activities and reaching commercialization.
Ascelia Pharma AB News
ACE FAQ
What was Ascelia Pharma AB’s price range in the past 12 months?
Ascelia Pharma AB lowest stock price was kr0.46 and its highest was kr3.55 in the past 12 months.
What is Ascelia Pharma AB’s market cap?
Ascelia Pharma AB’s market cap is kr105.76M.
When is Ascelia Pharma AB’s upcoming earnings report date?
Ascelia Pharma AB’s upcoming earnings report date is Nov 05, 2026 which is in 34 days.
How were Ascelia Pharma AB’s earnings last quarter?
Ascelia Pharma AB released its earnings results on Aug 20, 2026. The company reported -kr0.093 earnings per share for the quarter.
Is Ascelia Pharma AB overvalued?
According to Wall Street analysts Ascelia Pharma AB’s price is currently Overvalued.
Does Ascelia Pharma AB pay dividends?
Ascelia Pharma AB does not currently pay dividends.
What is Ascelia Pharma AB’s EPS estimate?
Ascelia Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ascelia Pharma AB have?
Ascelia Pharma AB has 133,535,460 shares outstanding.
What happened to Ascelia Pharma AB’s price movement after its last earnings report?
Ascelia Pharma AB reported an EPS of -kr0.093 in its last earnings report. Following the earnings report the stock price went up 7.273%.
Which hedge fund is a major shareholder of Ascelia Pharma AB?
Currently, no hedge funds are holding shares in SE:ACE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ascelia Pharma AB
Ascelia Pharma AB (publ) is a Swedish biotechnology company concentrating on the development of orphan drugs for cancer treatment. The firm is currently progressing Mangoral, an innovative non-gadolinium contrast agent, through Phase 3 clinical trials for magnetic resonance imaging (MRI) of the liver. Furthermore, it is advancing Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 development for gastric cancer therapy. Ascelia Pharma has also entered into a clinical collaboration agreement with Taiho Oncology, Inc. to develop Oncoral in combination with LONSURF. The company was established in 2000 and has its headquarters situated in Malmö, Sweden.
Technical Analysis
BioInvent International AB
―
Oncopeptides AB
―
OncoZenge AB
―
Immunicum AB
―
Cantargia AB
―